New antibiotics to fight drug-resistant bacteria
Official title: Novel antimicrobials to combat Gram-negative bacteria
Funded at University of Nebraska Medical Center · NIH-10888456 · Data updated 2026-11-12
This study is looking for new ways to fight tough bacteria like Klebsiella pneumoniae that don't respond to regular antibiotics, using special proteins to find treatments that can help people with infections caused by these resistant germs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | August 16, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $383,750 |
| NIH project number | 1R56AI175209-01 |
| Project ID | NIH-10888456 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from infections caused by Gram-negative bacteria, particularly those resistant to existing antibiotics.
✕Less likely to help
Patients with infections caused by non-Gram-negative bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
What this research studies
This research focuses on developing new antimicrobials to combat drug-resistant Gram-negative bacteria, particularly Klebsiella pneumoniae. The approach combines a unique database of antimicrobial peptides with structural biology to identify effective treatments. By utilizing advanced filtering technology and classification methods, the researchers aim to discover peptides that can eliminate bacteria resistant to conventional antibiotics. Preliminary results have shown promise in killing resistant bacteria and disrupting biofilms, which are often difficult to treat.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that effectively treat infections caused by drug-resistant bacteria.
How similar studies have gone: Other research has shown success in developing new antimicrobial peptides, indicating that this approach has potential for breakthroughs in treating resistant infections.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Wang, Guangshun — University of Nebraska Medical Center
- Study coordinator: Wang, Guangshun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.